Suven secures patents in 4 countries

Suven Life Sciences announced that it has secured patents in Australia, Canada, Japan, and New Zealand to one of its New Chemical Entity (NCE) for CNS therapy through new mechanism of action – H3 Inverse agonist.


(Photo Courtesy:

These patents are said to be valid until 2030.

The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.

Histaminargic dysfunction has been strongly associated with the cognitive and behavioral deficits observed in several CNS disorders such as Alzheimer's, ADHD, dementia, depression, Huntington's disease and Parkinson's disease.

H3 receptor blockade elevates acetylcholine in brain regions responsible for cognition, thus offer a means for targeting cognitive processes.

Novel, potent, selective, brain penetrant and orally active H3 receptor inverse agonist for the treatment of cognitive deficits would offer new line of treatment for this unmet medical need.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email